Patch Testing: The Patient Experience. Issue 5 (September 2021)

• Record Type: Journal Article
• Authors: Kimyon, Rebecca S.; Hylwa, Sara A.; Neeley, Anne B.; Warshaw, Erin M.
• Is Part Of: Dermatitis. Volume 32:Issue 5(2021)
• Publication Date: 2021-09
• Subjects: Skin -- Inflammation -- Periodicals; Skin -- Diseases -- Periodicals; Dermatology -- Periodicals; Dermatitis, Contact -- Periodicals; Dermatitis, Atopic -- Periodicals; Dermatitis, Occupational -- Periodicals; Drug Eruptions -- Periodicals; 616.51
• DOI: 10.1097/DER.0000000000000656
• Languages: English
• ISSNs: 1710-3568

Abstract

Abstract : Background: Data regarding patient-reported symptoms during patch testing are limited. Objective: To provide frequency of symptoms (pain, sleep difficulty, medication need, site itching, itch elsewhere, and worsening rash) experienced by patients undergoing extensive patch testing and to determine association of these symptoms with patient characteristics. Methods: This was a retrospective chart review of patients who underwent patch testing at a tertiary referral, contact dermatitis clinic over 15 months. Demographics, number of patches placed, patch location(s), and number of reactions (total and ++/+++) were extracted by chart review. Frequency of symptoms reported on a questionnaire administered at the 48-hour (48H) and final (F) visits was tabulated, and associations were evaluated using χ 2 and Fisher exact tests. Results: Six hundred forty-one patient records were accessed. The most common symptom was patch site itching (48H, 77.4%; F, 76.5%). Frequency of pain and sleep difficulty were significantly higher at 48H compared with F ( P < 0.0001). Worsening of rash was significantly higher at F compared with 48H ( P < 0.0001). The number of patches was significantly associated with all symptoms except sleep difficulty ( P ⩽ 0.0141). Patch location was significantly associated with pain, medication need, itch elsewhere, and worsening rash but not sleep difficulty or site itch ( P ⩽ 0.0257). The number of reactions (total and ++/+++) was significantly associated with all symptoms except itch elsewhere (total P ⩽ 0.0316; ++/+++: P ⩽ 0.0445). Conclusions: Most patients reported symptoms during patch testing, most commonly itching (at patch site and elsewhere), sleep difficulty, and need for medication. The number of positive patch test reactions (total and ++/+++) was the most common characteristic associated with the symptoms. Abstract : Supplemental digital content is available in the text.